MYCN and neuroblastoma: We have observed significant and durable responses to indisulam in multiple high-risk neuroblastoma models including PDXs derived from relapsed patient samples, transgenic MYCN/ALKF1178L mice, and tumors derived from C-MYC–overexpressing mice.